BMY ROE - Return on Equity
Profitability analysis for Bristol Myers Squibb Co
Stock Price
$55.92
+0.27% today
Return on Equity (ROE)
0.3%
Poor - Low capital efficiency
Key Profitability Metrics
Return on Equity
0.3%
Profit per dollar of equity
Return on Assets
0.1%
Profit per dollar of assets
Return on Invested Capital
0.3%
Profit per dollar invested
Industry Comparison
BMY ROE
0.3%
Health Care Average
12.0%
Difference
-11.7%
Below industry by 97.2%
BMY is underperforming Health Care peers, suggesting potential for operational improvements.
DuPont Analysis - ROE Breakdown
ROE can be decomposed into three components using the DuPont formula:
ROE = Net Margin × Asset Turnover × Equity Multiplier
Net Profit Margin
0.1%
Thin margins
Asset Turnover
0.00x
Capital intensive
Equity Multiplier
0.00x
Conservative
0.3% = 0.1% × 0.00 × 0.00
What ROE Means for Investors
Capital Efficiency
BMY's ROE of 0.3% shows moderate capital efficiency. There may be room for improvement in profitability.
Competitive Advantage
ROE below industry average may indicate competitive pressures, operational inefficiencies, or industry headwinds affecting Bristol Myers Squibb Co.
Growth Potential
With moderate ROE, BMY may need external financing or debt to fund significant growth initiatives, potentially diluting shareholders or increasing leverage.
Leverage Consideration
BMY has conservative leverage (0.0x equity multiplier), suggesting the ROE reflects genuine operational efficiency rather than financial engineering.
ROE Calculation Data
Most Recent Quarter
Net Income
$-$8.95B
Shareholders Equity
$16.34B
Formula
ROE = (Net Income / Shareholders Equity) × 100
Analyze BMY in Depth
View complete financial statements, quant models, and AI-powered insights
Frequently Asked Questions
What is BMY ROE (Return on Equity)?
BMY's Return on Equity (ROE) is 0.3%, which is considered poor. ROE measures how efficiently Bristol Myers Squibb Co generates profit from shareholders' equity. For every dollar of equity, BMY generates 0.3 cents in profit.
Is BMY ROE good or bad?
BMY's ROE of 0.3% is poor and below the Health Care average of approximately 12.0%. Low capital efficiency. It trails industry peers by 97.2%.
What is the difference between ROE, ROA, and ROIC?
ROE (Return on Equity) at 0.3% measures returns on shareholder equity. ROA (Return on Assets) at 0.1% measures how efficiently BMY uses its total assets. ROIC (Return on Invested Capital) at 0.3% shows returns on all capital invested, including debt. All three metrics help evaluate Bristol Myers Squibb Co's profitability from different angles.
How does BMY generate its ROE?
BMY generates its 0.3% ROE through the DuPont formula: Net Margin (0.1%) × Asset Turnover (0.00) × Equity Multiplier (0.00). This shows thin profit margins, capital-intensive operations, and conservative capital structure.
Should I invest in BMY based on ROE?
While BMY's ROE of 0.3% is poor, ROE alone shouldn't determine investment decisions. Moderate ROE suggests steady but unexceptional returns. Consider ROE alongside other metrics like debt levels, growth rates, valuation multiples, and industry trends before investing.
What factors affect BMY Return on Equity?
BMY's ROE is affected by three key drivers: (1) Profitability - net margins from pricing power and cost management, (2) Efficiency - how well Bristol Myers Squibb Co uses its assets to generate sales, and (3) Leverage - the amount of debt used to finance operations. Health Care sector dynamics, competitive positioning, management quality, and economic conditions all impact these drivers.
Disclaimer: ROE analysis is based on publicly available financial data and should not be considered financial advice. High ROE can be misleading if driven primarily by excessive leverage. Always analyze multiple metrics and consider your own research before making investment decisions.